Filing Details
- Accession Number:
- 0001209191-15-028985
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-03-24 18:10:38
- Reporting Period:
- 2015-03-23
- Filing Date:
- 2015-03-24
- Accepted Time:
- 2015-03-24 18:10:38
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1197032 | F Ian Smith | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp & Cfo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2015-03-23 | 200 | $122.44 | 123,976 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2015-03-23 | 200 | $123.52 | 123,776 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2015-03-23 | 1,327 | $124.87 | 122,449 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2015-03-23 | 2,815 | $125.69 | 119,634 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2015-03-23 | 1,000 | $126.65 | 118,634 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2015-03-23 | 500 | $127.83 | 118,134 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 5,306 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $122.44 (range $122.10 to $122.78).
- Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $123.52 (range $123.10 to $123.93).
- Open market sales reported on this line occurred at a weighted average price of $124.87 (range $124.28 to $125.24).
- Open market sales reported on this line occurred at a weighted average price of $125.69 (range $125.28 to $126.24).
- Open market sales reported on this line occurred at a weighted average price of $126.65 (range $126.29 to $127.07).
- Open market sales reported on this line occurred at a weighted average price of $127.83 (range $127.39 to $128.19).
Billionaire Hedge Funds
